BURZIK CATHERINE M
BURZIK CATHERINE M's purchase track record
BURZIK CATHERINE M has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/19/2021 | OFIX | $50K | +1.2% | -13.7% | -17.0% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Orthofix pays $24M in damages to former executives. Orthofix Medical has paid $24 million in damages to former executives. This significant cash outflow may impact the company's financial position. The stock currently trades near its 52-week low, with analysts averaging a $13 target price.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Haemonetics Gets Price Target Hikes Amid Recent Stock Jump. Barrington Research and Mizuho both raised their price targets for Haemonetics to $140, maintaining Outperform ratings. This follows a recent 17.5% jump in the stock, which is now trading near its 52-week high. While some analysts note the current price may not be an ideal entry point, the firm's outlook has improved due to CSL Plasma developments.
Transaction History
| BDX | ▲ Buy | Grant | 930 | $0 | 1/28/2025 | View on chart |
| OFIX | ▼ Sell | Tax Withholding | 47,486 | $676K | 4/8/2024 | View on chart |
| BDX | ▲ Buy | Grant | 900 | $0 | 1/23/2024 | View on chart |
| OFIX | ▲ Buy | Grant | 120,676 | $0 | 10/15/2023 | View on chart |
| OFIX | ▲ Buy | Grant | 3,589 | $0 | 6/19/2023 | View on chart |
| BDX | ▲ Buy | Grant | 848 | $0 | 1/24/2023 | View on chart |
| OFIX | ▲ Buy | Grant | 14,052 | $0 | 1/5/2023 | View on chart |
| HAE | ▲ Buy | Grant | 2,730 | — | 8/5/2022 | View on chart |
| OFIX | ▲ Buy | Grant | 8,844 | $0 | 6/6/2022 | View on chart |
| BDX | ▲ Buy | Grant | 820 | $0 | 1/25/2022 | View on chart |
| OFIX | ▲ Buy | Open Market | 1,660 | $50K | 11/19/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
BDX Revello Stent Trial Success, Revenue Up 5.4%, Earnings Down 34%
The company announced that its Revello stent achieved strong results in the AGILITY trial for peripheral artery disease patients. Revenue rose 5.4% year‑over‑year, but net earnings fell 34.3%, reflecting higher costs or lower margins. The dividend yield sits at 1.59% and analysts see a target of $194, while the stock trades near the top of its 52‑week range.
BDX Revello Stent Trial Success, Revenue Up 5.4%, Earnings Down 34%. The company announced that its Revello stent achieved strong results in the AGILITY trial for peripheral artery disease patients. Revenue rose 5.4% year‑over‑year, but net earnings fell 34.3%, reflecting higher costs or lower margins. The dividend yield sits at 1.59% and analysts see a target of $194, while the stock trades near the top of its 52‑week range.